Complement 4d Antibody [CPT4d-1]
| Code | Size | Price |
|---|
| PSI-33-880-100ug | 100ug | £765.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1, kappa
Antibody Clonality: Monoclonal
Antibody Clone: CPT4d-1
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
Shipping:
blue ice
Storage:
Aliquot and Store at -20C. Avoid freez-thaw cycles.
Documents
Further Information
Application Note:
IF: 1:50-1:100
IHC (FFPE): 1:200-1:400 for 30 minutes at RT (1)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the C4d antibody to be titered up or down for optimal performance.
IHC (FFPE): 1:200-1:400 for 30 minutes at RT (1)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the C4d antibody to be titered up or down for optimal performance.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes.
Background:
This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.
Buffer:
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration:
0.2 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Human protein was used as the immunogen for this C4d antibody.
NCBI Gene ID #:
720 & 721
NCBI Official Name:
complement C4A (Rodgers blood group) & complement C4B (Chido blood group)
NCBI Official Symbol:
C4A & C4B
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Purification:
Protein G affinity chromatography
Research Area:
Immunology
Swissprot #:
P0C0L4 & P0C0L5
User NOte:
Optimal dilutions for each application to be determined by the researcher